Clinical trials: Hematology
Lymphoma, Leukemia
Phase I Study of Sequential Cord Blood Transplants
The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00299767
- Testing
- sequential cord blood transplantation
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Neoplasms, Hematologic
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with…
- Trial name
- NCT01594723
- Testing
- 120 mg LY2784544
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Chronic Myelogenous Leukemia - Chronic Phase
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior…
- Trial name
- AIM4CML (NCT04666259)
- Testing
- ABL001
- Where
- 26 sites in United States
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoid
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
This clinical trial is an open-label, multicenter, prospective phase 2 clinical trial targeting pediatric leukemia patients of infant age.
- Trial name
- NCT06516679
- Testing
- Consolidation #4(without daunorubicin), Consolidation #4(with daunorubicin), Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)
- Where
- 10 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion…
- Trial name
- NCT07084896
- Testing
- Belantamab mafodotin, Nirogacestat
- Where
- 29 sites in United States, Australia and 11 more
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses.
- Conditions
- Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma
- Trial name
- NCT00112827
- Testing
- total marrow irradiation, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Morphological Markers of Gastroesophageal Reflux Disease (GERD)
The purpose of this project is to learn more about a new and promising way to diagnose acid reflux disease using a very high-powered microscope.
- Trial name
- NCT01921686
- Testing
- Sample collection and Questionnaire
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Thalassemia in Children
Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
The objective of this observational study is to investigate the long-term effects of Hetrombopag in promoting platelet engraftment during haploidentical hematopoietic stem cell transplantation (HSCT) in children with thalassemia…
- Trial name
- NCT07003269
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Iron-deficiency, Transplant-Related Disorder
Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation
Iron deficiency is common in kidney transplant recipients and is associated with impaired exercise tolerance and an unfavourable prognosis.
- Trial name
- EFFECT-KTx (NCT03769441)
- Testing
- Ferric carboxymaltose, Sodium chloride
- Where
- 2 sites in Netherlands
- Volunteers
- 148 people
- Sponsor
- University Medical Center Groningen
Myelofibrosis
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to…
- Trial name
- NCT04576156
- Testing
- Imetelstat, Best Available Therapy (BAT)
- Where
- 144 sites in United States, Argentina and 24 more
- Volunteers
- 327 people
- Sponsor
- Geron Corporation
Myelodysplastic Syndrome
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
This study will evaluate the safety and tolerability of eltrombopag in the treatment of low platelet counts in adult subjects with advanced myelodysplastic syndrome (MDS), secondary acute myeloid leukemia after MDS (sAML/MDS), or…
- Trial name
- NCT00903422
- Testing
- eltrombopag olamine
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 98 people
- Sponsor
- GlaxoSmithKline
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care…
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Chronic Conditions
- Trial name
- NCT04595851
- Testing
- Patient Reported Outcome Measure (PROM), Comprehensive Medication Review (CMR), Communications between oncology and primary care pharmacists
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Graft Versus Host Disease
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
The purpose of this study was to test whether a new drug named visilizumab would decrease the severity of graft-versus-host disease in patients treated with a mismatched donor.
- Trial name
- NCT00720629
- Testing
- Visilizumab, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Thalassemia
Pharmacotherapy Prescribing Pattern and the Adherence Level to Iron Chelation Therapy in Thalassemia
Thalassemias are a heterogeneous grouping of genetic disorders that result in dysfunctional Hb, reduced RBC life span leading to chronic anemia . Thalassemia is endemic in the Middle East.
- Trial name
- NCT06210139
- Where
- Iraq
- Volunteers
- 199 people
- Sponsor
- Reem Ali Shaker
Myelofibrosis, Primary Myelofibrosis
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant ruxolitinib.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT03373877
- Testing
- PU-H71, Ruxolitinib
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.
Congenital Bleeding Disorder, Haemophilia A
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Trial name
- NCT01220141
- Testing
- activated recombinant human factor VII
- Where
- 14 sites in Argentina, Austria and 12 more
- Volunteers
- 51 people
- Sponsor
- Novo Nordisk A/S
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, B-cell, Lymphoma, Hodgkins
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a procedure that transplants bone marrow cells (stem cells) from a matching donor into a recipient in order to allow the donor stem cells to produce…
- Conditions
- Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
- Trial name
- NCT01087294
- Testing
- Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies
- Trial name
- NCT06756451
- Testing
- RJK-RT2831 dose-escalation phase Ia, RJK-RT2831 Dose Expansion Phase Ib
- Where
- 16 sites in China
- Volunteers
- 71 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Thalassemia Major
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major.
- Trial name
- NCT01740531
- Testing
- S-303 Treated Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells
- Where
- 3 sites in Italy, Turkey (Türkiye)
- Volunteers
- 86 people
- Sponsor
- Cerus Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.